Cephalon ends Vivitrol deal with Alkermes
This article was originally published in Scrip
Executive Summary
Cephalonhas ended its Vivitrol (naltrexone extended-release) collaboration with Alkermesafter reviewing its pipeline. The marketing rights to the treatment for alcohol dependency will revert back to Alkermes, which will dedicate its resources towards increasing the product’s sales.